The Oncosearch | Oncotarget

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson, Fanny Wunder, Giulia Pretelli, Agatha Martin Casado, Wafik S. El-Deiry

Published Jun 9, 2025 · Vol. 16, No. 1 · pp. 456-466

Keywords: cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson, Fanny Wunder, Giulia Pretelli, Agatha Martin Casado, Wafik S. El-Deiry

Published Jun 9, 2025

Keywords: cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells Research Paper

Astha Lamichhane, Gary D. Luker, Seema Agarwal, Hossein Tavana

Published Sep 25, 2023 · Vol. 14, No. 1 · pp. 879-889

Keywords: drug resistance, cancer stem cells, patient-derived tumor model, colorectal cancer, combination treatment

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment Research Paper

Valentin Feichtenschlager, Yixuan James Zheng, Wilson Ho, Linan Chen, Ciara Callanan, Christopher Chen, Albert Lee, Jose Ortiz, Klemens Rappersberger, Susana Ortiz-Urda

Published May 19, 2023 · Vol. 14, No. 1 · pp. 543-560

Keywords: MALAT1, MAPK-pathway, BRAF, melanoma, antisense oligonucleotides

Correction: Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer Correction

Igor Vujic, Martina Sanlorenzo, Christian Posch, Rosaura Esteve-Puig, Adam J. Yen, Andrew Kwong, Aaron Tsumura, Ryan Murphy, Klemens Rappersberger, Susana Ortiz-Urda

Published Oct 29, 2021

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Kelsey E. Huntington, Anna Louie, Lanlan Zhou, Wafik S. El-Deiry

Published Sep 11, 2021 · Vol. 12, No. 20 · pp. 1980-1991

Keywords: cytokine profiling, inflammatory response, chemokine, growth factor, immune profiling

MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways Research Paper

Alice Augenlicht, Manuel Saiselet, Myriam Decaussin-Petrucci, Guy Andry, Jacques E. Dumont, Carine Maenhaut

Published Jul 17, 2021 · Vol. 12, No. 16 · pp. 1587-1599

Keywords: miRNA, papillary thyroid carcinoma, IRS2, MAPK, PI3K

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

Rolando Pérez-Lorenzo, Stephanie O. Erjavec, Angela M. Christiano, Raphael Clynes

Published Jan 6, 2021 · Vol. 12, No. 2 · pp. 66-80

Keywords: anti-tumor antibodies, targeted therapy, immunotherapy, combination therapies, melanoma

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020 · Vol. 11, No. 46 · pp. 4201-4223

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

Michael E. Clark, Helen Rizos, Michelle R. Pereira, Ashleigh C. McEvoy, Gabriela Marsavela, Leslie Calapre, Katie Meehan, Olivia Ruhen, Muhammad A. Khattak, Tarek M. Meniawy, Georgina V. Long, Matteo S. Carlino, Alexander M. Menzies, Michael Millward, Melanie Ziman, Elin S. Gray

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 4016-4027

Keywords: melanoma, targeted therapy, drug resistance, BRAF splicing, extracellular vesicles

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

Douglas B. Johnson, Caroline A. Nebhan, Marcus S. Noel

Published Oct 22, 2020 · Vol. 11, No. 44 · pp. 3900-3903

Keywords: trametinib, MEK, BRAF, atypical, fusion

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Nathan M. Merrill, Nathalie M. Vandecan, Kathleen C. Day, Phillip L. Palmbos, Mark L. Day, Aaron M. Udager, Sofia D. Merajver, Matthew B. Soellner

Published Oct 3, 2020 · Vol. 11, No. 44 · pp. 3921-3932

Keywords: bladder cancer, drug screen, 3D culture, basal bladder cancer, MEK inhibition

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Hengyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew J. LaMarche, Morvarid Mohseni, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Huai-Xiang Hao

Published Jan 21, 2020 · Vol. 11, No. 3 · pp. 265-281

Keywords: SHP2, FGFR, resistance, feedback activation

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Hengyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew LaMarche, Morvarid Mohseni, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Huai-Xiang Hao

Published Jan 6, 2020

Keywords: SHP2, FGFR, resistance, feedback activation

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

Thomas B. Davis, Mingli Yang, Heiman Wang, Changgong Lee, Timothy J. Yeatman, W. Jack Pledger

Published Nov 26, 2019 · Vol. 10, No. 63 · pp. 6768-6780

Keywords: colorectal cancer, PTPRS, ERK, SRC, adaptive resistance

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Rowland H. Han, Gavin P. Dunn, Milan G. Chheda, Albert H. Kim

Published Nov 19, 2019 · Vol. 10, No. 62 · pp. 6739-6753

Keywords: brain metastases, targeted therapy, precision medicine, immunotherapy, systemic therapy

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper

Alexander K. Verma, Shanta M. Messerli, W. Keith Miskimins

Published Nov 15, 2019 · Vol. 11, No. 17 · pp. 1493-1504

Keywords: oropharyngeal cancer, lactate, Ras, anti-tumor immunity, PD-L1

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Tatsuya Kawase, Taisuke Nakazawa, Tomohiro Eguchi, Hirofumi Tsuzuki, Yoko Ueno, Yasushi Amano, Tomoyuki Suzuki, Masamichi Mori, Taku Yoshida

Published Oct 22, 2019 · Vol. 10, No. 58 · pp. 6111-6123

Keywords: FLT3, FL, FLT3 inhibitor, gilteritinib, antitumor activity

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard, Sigmund Hsu

Published Oct 15, 2019 · Vol. 10, No. 57 · pp. 6038-6042

Keywords: papillary, craniopharyngioma, BRAF V600E, dabrafenib, neuro-oncology

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells Research Paper

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment Research Paper

Correction: Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer Correction

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways Research Paper

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells Research Paper

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment Research Paper

Correction: Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer Correction

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways Research Paper

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies Research Paper

MEK inhibitors in non-V600 BRAF mutations and fusions Research Perspective

MEK is a promising target in the basal subtype of bladder cancer Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR Research Paper

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC Priority Research Paper

The impact of systemic precision medicine and immunotherapy treatments on brain metastases Review

Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma Research Paper

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Research Paper

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report Case Report

Lactate induces PD-L1 in HRAS^G12V-positive oropharyngeal squamous cell carcinoma Research Paper